BioAtla (NASDAQ:BCAB) is a clinical-stage biotechnology company focused on the discovery and development of conditionally active biologics (CABs) designed to achieve targeted activity in the tumor microenvironment while minimizing off-tumor effects. Utilizing its proprietary CAB platform, the company engineers antibodies and antibody–drug conjugates (ADCs) that remain inactive under normal physiological conditions but become activated by factors such as low pH, elevated protease activity, or hypoxia commonly found in solid tumors. This approach is intended to enhance therapeutic window and safety profiles compared with conventional antibody therapies.
The company’s pipeline features multiple oncology candidates across preclinical and clinical stages. Lead programs include anti-EGFR ADCs and novel targets such as CDH6 and AXL, each designed to leverage CAB technology for selective tumor targeting. In addition to oncology assets, BioAtla is advancing conditionally active antibody approaches in immuno-oncology, exploring combinations with checkpoint inhibitors and other immune modulators to potentiate anti-tumor responses. Collaborative partnerships in Greater China and other territories aim to accelerate development and regional registration efforts.
Founded in 2008 and headquartered in San Diego, California, BioAtla maintains research operations in Shanghai, China, reflecting its global footprint in antibody discovery and translational research. The company completed its initial public offering on the Nasdaq in 2020 and has since expanded its team of scientists, clinicians, and regulatory experts. Facilities in the U.S. and China support integrated discovery, process development, and manufacturing partnerships, enabling streamlined progression of CAB candidates from bench to clinic.
BioAtla is led by a management team with extensive experience in antibody engineering and biopharmaceutical development. Chairman and Chief Executive Officer Dr. Xiaodong Yang, Ph.D., brings more than two decades of antibody discovery expertise, having held senior leadership roles at several biotech firms. Supported by a seasoned board of directors and scientific advisory panel, the company is positioned to advance its innovative CAB platform toward potential transformational therapies for cancer patients worldwide.
